Baxter International
BAX
$21.55
+2.42%
Baxter International Inc. is a global healthcare company that manufactures and supplies a broad portfolio of essential medical products, including injectable therapies, IV pumps, surgical sealants, hospital beds, and patient monitoring equipment. The company operates as a significant, established player in the medical instruments and supplies industry, having expanded its hospital-focused offerings through the acquisition of Hillrom in 2021. The current investor narrative is dominated by significant operational and financial headwinds, including a recent manufacturing disruption affecting a critical cancer drug supply in Europe and disappointing 2026 profit guidance that has pressured the stock, raising questions about the company's near-term profitability and turnaround prospects.…
BAX
Baxter International
$21.55
Related headlines
Investment Opinion: Should I buy BAX Today?
Rating: Hold. The core thesis is that BAX is a deeply troubled company trading at a distressed valuation; the significant operational risks currently outweigh the potential value opportunity, making it unsuitable for new capital except for highly risk-tolerant investors seeking a speculative turnaround.
Supporting evidence for this cautious stance includes: 1) The stock trades at a severely depressed PS ratio of 0.87, suggesting the market has priced in substantial failure. 2) However, profitability metrics are alarming, with a trailing net margin of -8.5% and a quarterly gross margin that recently collapsed to 19.4%. 3) While free cash flow of $323M is positive, the forward PE of 9.88x implies the market expects a sharp earnings recovery that is far from guaranteed. 4) Analyst sentiment is mixed and cautious, with recent institutional ratings ranging from 'Overweight' to 'Underweight', reflecting profound uncertainty.
The thesis would upgrade to a Buy if the company demonstrates consecutive quarters of gross margin stabilization above 30% and provides evidence that the Q4 2025 loss was an anomaly. It would downgrade to a Sell if revenue growth turns negative, free cash flow turns negative, or the stock breaks decisively below its 52-week low of $15.73. Relative to its own distressed history and the severity of its current problems, the stock appears fairly valued—neither clearly overvalued nor undervalued—as the deep sales multiple discount appropriately balances the company's substantial execution risk.
Sign up to view all
BAX 12-Month Price Forecast
The outlook for BAX is one of high uncertainty centered on execution risk. The stock is priced for distress, but the underlying fundamentals are genuinely distressed. The base case of a protracted, challenging turnaround is most probable, leading to a range-bound stock. The stance would upgrade to bullish on clear evidence of margin recovery and debt reduction, likely requiring two consecutive quarters of improved profitability. It would turn bearish if the company fails to generate positive operating income or if liquidity concerns emerge. The low beta offers some defensive characteristics, but the primary driver will be company-specific operational performance.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Baxter International's 12-month outlook, with a consensus price target around $28.02 and implied upside of +30.0% versus the current price.
Average Target
$28.02
8 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
8
covering this stock
Price Range
$17 - $28
Analyst target range
A modest cohort of 8 analysts covers the stock, indicating it is a mid-to-large-cap company with sustained institutional interest. The consensus recommendation leans neutral-to-cautious, with recent institutional ratings from firms like Citigroup and Goldman Sachs at 'Neutral', Barclays at 'Overweight', and Morgan Stanley at 'Underweight', reflecting a divided and uncertain outlook. The average analyst revenue estimate for the upcoming period is $11.89 billion, with a tight range between $11.88 billion and $11.90 billion, suggesting strong consensus on the top-line forecast. However, specific price targets and a clear Buy/Hold/Sell distribution are not provided in the data, making it impossible to calculate a precise implied upside or downside from the current price. The lack of explicit price target data limits the ability to gauge the strength of analyst conviction, though the recent news of downgraded 2026 profit guidance and supply chain issues likely weighs on target prices. The tight range on revenue estimates contrasts with the wide dispersion in stock ratings, indicating analysts agree on the revenue trajectory but disagree profoundly on how to value the company given its profitability challenges and operational headwinds.
Bulls vs Bears: BAX Investment Factors
The evidence currently favors the bear case, given the severity and recency of the profitability collapse and disappointing forward guidance. The bull case rests primarily on a deep valuation discount and a recent technical bounce, which may be a temporary relief rally. The single most important tension in the investment debate is whether the catastrophic Q4 2025 margin compression and losses represent a one-time operational failure or a symptom of deeper, structural challenges that will prevent a meaningful earnings recovery. The resolution of this issue—through subsequent quarterly results—will determine if the stock's extreme undervaluation is a trap or an opportunity.
Bullish
- Extreme Valuation Discount: The stock trades at a trailing Price-to-Sales ratio of 0.87, near the bottom of its historical range and significantly below its peak of 14.46 in 2021. This deep discount prices in severe pessimism, offering a potential margin of safety if operations stabilize.
- Strong Recent Technical Rebound: BAX has sharply outperformed the market over the past three months, gaining 23.2% versus the SPY's 15.1%. This technical momentum, following a -50% drawdown, suggests a potential mean reversion and investor appetite at depressed levels.
- Positive Free Cash Flow Generation: Despite recent losses, the company generated $323 million in TTM free cash flow, providing crucial internal funding capacity. This liquidity supports ongoing operations and mitigates immediate financial distress risks.
- Analyst Consensus on Revenue Stability: Analysts show strong agreement on the top-line forecast, with a tight revenue estimate range of $11.88B to $11.90B for the upcoming period. This consensus suggests the core business is not in a revenue collapse scenario.
Bearish
- Severe Profitability Collapse: Q4 2025 saw a catastrophic net loss of -$1.13B, with gross margin collapsing to 19.4% from 35.2% in Q2 2025. This extreme volatility and negative net margin of -37.9% signal deep operational inefficiencies and potential structural problems.
- Disappointing 2026 Profit Guidance: Recent news highlights that management's 2026 profit guidance fell below expectations, creating significant near-term headwinds. This weak outlook, coupled with a recent cancer drug supply disruption in Europe, pressures the turnaround narrative.
- Elevated Financial Leverage: The company carries a debt-to-equity ratio of 1.63, indicating a leveraged capital structure. This high leverage amplifies risks if profitability does not recover, potentially limiting financial flexibility.
- Poor Asset Utilization: Return on Equity is deeply negative at -15.6%, and Return on Assets is a minimal 2.85%. These metrics reflect substantial losses eroding shareholder equity and poor efficiency in generating profits from its asset base.
BAX Technical Analysis
The stock is in a pronounced long-term downtrend, with a 1-year price change of -33.255%, significantly underperforming the broader market. As of the latest data, the price of $19.89 sits approximately 37% above its 52-week low of $15.73 but remains 37% below its 52-week high of $31.76, indicating it is trading in the lower-middle portion of its annual range, which reflects persistent bearish sentiment but may also suggest a potential stabilization zone after a steep decline. Recent momentum shows a notable short-term recovery, with the stock up 8.5106% over the past month and 23.1579% over the past three months, sharply outperforming the SPY's gains of 0.74% and 15.14%, respectively; this divergence from the longer-term downtrend could signal a technical rebound or mean reversion, though it follows a severe drawdown of -50.19%. Key technical levels are clearly defined, with immediate support at the 52-week low of $15.73 and major resistance at the 52-week high of $31.76; a sustained breakout above the recent recovery highs near $22 would be needed to signal a more durable trend reversal, while a breakdown below $15.73 would likely trigger a new leg down. The stock's beta of 0.642 indicates it is approximately 36% less volatile than the broader market, which is typical for a large-cap healthcare supplier and suggests its recent extreme price moves are driven more by company-specific fundamentals than systemic market risk.
Beta
0.64
0.64x market volatility
Max Drawdown
-50.2%
Largest decline past year
52-Week Range
$16-$32
Price range past year
Annual Return
-29.6%
Cumulative gain past year
| Period | BAX Return | S&P 500 |
|---|---|---|
| 1m | +11.2% | -2.2% |
| 3m | +34.9% | +15.8% |
| 6m | +11.2% | +6.4% |
| 1y | -29.6% | +20.9% |
| ytd | +10.5% | +7.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BAX Fundamental Analysis
Revenue growth has been modest but inconsistent, with the most recent quarterly revenue of $2.974 billion representing an 8.03% year-over-year increase; however, this follows a volatile pattern across recent quarters, with Q4 2025 revenue up from $2.753 billion in Q4 2024 but down sequentially from $2.835 billion in Q3 2025. Segment data shows Medical Products and Therapies contributed $1.388 billion, Healthcare Systems and Technologies $827 million, and Pharmaceuticals $668 million in the latest period, indicating a diversified but challenged portfolio. The company is currently deeply unprofitable, with a net income of -$1.128 billion in Q4 2025, resulting in a net margin of -37.9% and a trailing EPS of -$2.16; gross margin collapsed to 19.4% in that quarter from 35.2% in Q2 2025, highlighting severe margin compression and operational inefficiencies, though the trailing twelve-month gross margin stands at 30.05%. Profitability has been highly erratic, swinging from a net income of $126 million in Q1 2025 to the massive Q4 loss, underscoring significant volatility in earnings quality. The balance sheet shows elevated financial leverage with a debt-to-equity ratio of 1.632, indicating a leveraged capital structure. However, liquidity appears adequate with a current ratio of 2.31, and the company generated positive free cash flow of $323 million on a TTM basis, providing some internal funding capacity. Return on equity is deeply negative at -15.6%, reflecting the substantial losses eroding shareholder equity, while return on assets is a minimal 2.85%, indicating poor asset utilization efficiency.
Quarterly Revenue
$3.0B
2025-12
Revenue YoY Growth
+0.08%
YoY Comparison
Gross Margin
+0.19%
Latest Quarter
Free Cash Flow
$323000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BAX Overvalued?
Given the negative net income and EPS of -$2.16, the primary valuation metric selected is the Price-to-Sales (PS) ratio. The stock trades at a trailing PS ratio of 0.872, which is exceptionally low and reflects the market's severe discounting due to profitability concerns. A forward PE ratio of 9.88x is available, but this is based on estimated future profitability and the significant gap between the negative trailing PE of -10.92x and the positive forward PE implies the market expects a sharp recovery in earnings, though this hinges on the company's guidance being achieved. Compared to industry averages, the PS ratio of 0.872 is difficult to contextualize without a direct peer average, but it suggests a deep discount relative to the company's own sales base, likely pricing in substantial margin and execution risks. The EV/Sales multiple of 1.609 provides a similar enterprise-level view of a subdued valuation. Historically, the stock's own valuation has compressed dramatically; its current PS ratio of 0.872 is near the very bottom of its observable historical range, which has seen PS ratios as high as 14.46 in early 2021. Trading near historical valuation lows suggests the market has priced in significant pessimism, potentially offering a value opportunity if the company can stabilize operations, but it also signals a lack of confidence in a near-term fundamental recovery.
PE
-10.9x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -64x~149x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
23.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are severe and center on profitability. The company's net income swung from +$126M in Q1 2025 to -$1.13B in Q4 2025, demonstrating extreme earnings volatility and poor quality. Gross margin collapsed from 35.2% to 19.4% in just two quarters, indicating potential pricing pressure, cost inflation, or operational breakdowns. While free cash flow remains positive at $323M TTM, the debt-to-equity ratio of 1.63 creates a leveraged capital structure that is vulnerable if margins do not recover. The company's guidance for 2026 profits already signals management expects continued challenges.
Market & Competitive Risks include valuation compression and external cost pressures. The stock trades at a PS ratio of 0.87, near historical lows, suggesting the market has already priced in significant distress. However, further multiple compression is possible if the earnings recovery implied by the forward PE of 9.88x fails to materialize. Recent news highlights a dual threat: a manufacturing disruption affecting a critical cancer drug supply in Europe and rising petrochemical costs from geopolitical tensions in the Strait of Hormuz, which analysts warn could pressure medical supply margins within weeks. The stock's low beta of 0.64 offers little protection against these company-specific headwinds.
Worst-Case Scenario involves a failure to stabilize operations, leading to a liquidity crisis. The chain of events would be: 1) Q4 margin weakness persists into 2026, 2) the 2026 profit guidance is missed, triggering further analyst downgrades, 3) rising input costs from supply chain disruptions further compress already thin margins, and 4) high debt leverage limits strategic options, forcing dilutive financing or asset sales. In this scenario, the stock could retest and break below its 52-week low of $15.73. Given the current price of ~$19.89, this represents a realistic downside of approximately -21%. A more severe bear case, aligning with the stock's maximum drawdown of -50.19%, suggests theoretical downside to the ~$10 range, though that would likely require a fundamental credit event.
FAQ
The key risks are, in order of severity: 1) Operational Risk: The company has demonstrated extreme earnings volatility and a recent collapse in gross margin to 19.4%, indicating potential structural issues. 2) Financial Risk: A debt-to-equity ratio of 1.63 creates leverage that amplifies losses and could limit flexibility. 3) Guidance & Execution Risk: Management's disappointing 2026 profit guidance and recent supply chain disruptions (like the European cancer drug issue) signal near-term headwinds. 4) Macro/Input Cost Risk: Recent news warns of rising petrochemical costs from geopolitical tensions, which could pressure margins for medical supplies further.
The 12-month forecast is highly bifurcated, with a base case target range of $19-$23 (50% probability), a bull case of $26-$32 (25% probability) if operations stabilize, and a bear case of $15.7-$18 (25% probability) if challenges deepen. The most likely scenario is a range-bound stock as the company works through its operational issues, with revenue stable near $12B but profitability recovering slowly. The key assumption behind the base case is that the catastrophic Q4 2025 results represent a low point, but the path to normalized earnings will be protracted and uneven.
BAX appears fairly valued relative to its current distressed state. The trailing PS ratio of 0.87 is near historical lows and suggests the market is pricing in significant failure, which aligns with the company's negative net margin and earnings volatility. The forward PE of 9.88x implies the market expects a profit recovery, but this is highly uncertain. Compared to a typical stable medical supplies peer, BAX would be considered undervalued on a sales basis, but given its own profitability crisis and high leverage, the discount is warranted. The valuation implies the market expects a challenging and slow recovery, not a rapid rebound.
BAX is a high-risk, speculative investment rather than a conventionally 'good' buy. It trades at a deep discount with a PS ratio of 0.87, but this reflects severe operational problems, including a recent quarterly net loss of -$1.13B and collapsed gross margins. The stock could be a good buy only for deep-value, patient investors willing to bet on a multi-year turnaround and who can tolerate the risk of further declines, including a potential -21% drop to its 52-week low. For most investors, it is more appropriate to hold and monitor rather than initiate a new position.
BAX is strictly a long-term, speculative investment for investors with a 3-5 year horizon. The company's turnaround, if it occurs, will take multiple quarters to demonstrate convincingly. The stock's low beta of 0.64 and lack of a reliable earnings stream make it a poor candidate for short-term trading, as catalysts are more likely to be negative (missed guidance, operational issues) than positive in the near term. The 2.5% dividend yield provides a minor income cushion but is not sufficient to justify a short-term hold. A minimum holding period of 18-24 months is suggested to properly assess the success or failure of the stabilization efforts.